Margaret Gamalo
Margaret (Meg) Gamalo-Siebers is a Filipino-American biostatistician and drug development executive specializing in inflammation and immunology. She works for Pfizer as vice president – biostatistics, global product development – inflammation and immunology, and is editor-in-chief of the Journal of Biopharmaceutical Statistics.[1][2]
Education and career
[edit]Gamalo earned a master's degree in applied mathematics and operations research from the University of the Philippines. She completed a Ph.D. in statistics at the University of Pittsburgh,[3] in 2006.[4]
She worked in the Center for Drug Evaluation and Research at the US Food and Drug Administration, and as a principal research scientist and research advisor for global statistical sciences at Eli Lilly, before taking her present position at Pfizer.[1][3][4]
Recognition
[edit]Gamalo was named as a Fellow of the American Statistical Association, in the 2023 class of fellows.[5]
References
[edit]- ^ a b Seifu, Yodit; Chang, Victoria; Lin, Junjing (December 1, 2020), "An Interview with Margaret Gamalo, Editor of JBS", Amstat News, American Statistical Association, retrieved 2023-10-16
- ^ "Editorial board", Journal of Biopharmaceutical Statistics web site, Taylor & Francis, retrieved 2023-10-16
- ^ a b Schacht, Alexander (November 9, 2021), "How to combine a control arm with RWE data: Interview with Margaret Gamalo", The Effective Statistician, retrieved 2023-10-16
- ^ a b Past graduates, University of Pittsburgh Department of Statistics, retrieved 2023-10-16
- ^ 2023 ASA Fellows (PDF), American Statistical Association, retrieved 2023-10-16
| Authority control databases: Academics |
|---|
